Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery.

[1]  B. Liu,et al.  The efficacy and safety of prophylactic use of levosimendan on patients undergoing coronary artery bypass graft: a systematic review and meta-analysis , 2019, Journal of Anesthesia.

[2]  Xiao-qiang Wu,et al.  Effects of levosimendan on mortality in patients undergoing cardiac surgery: A systematic review and meta‐analysis , 2018, Journal of cardiac surgery.

[3]  H. Thiele,et al.  Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. , 2018, The Cochrane database of systematic reviews.

[4]  T. Cassina,et al.  Perioperative levosimendan in cardiac surgery: A systematic review with meta-analysis and trial sequential analysis. , 2018, International journal of cardiology.

[5]  G. Chatellier,et al.  Effect of Levosimendan on Low Cardiac Output Syndrome in Patients With Low Ejection Fraction Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass: The LICORN Randomized Clinical Trial , 2017, Journal of the American Medical Association (JAMA).

[6]  R. Bellomo,et al.  Levosimendan for Hemodynamic Support after Cardiac Surgery , 2017, The New England journal of medicine.

[7]  K. Anstrom,et al.  Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery , 2017, The New England journal of medicine.

[8]  K. Anstrom,et al.  Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial , 2016, American heart journal.

[9]  R. Mehta,et al.  Preoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion. , 2015, International journal of cardiology.

[10]  V. Hasselblad,et al.  Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis. , 2013, Journal of cardiothoracic and vascular anesthesia.

[11]  R. Levin,et al.  Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. , 2012, Experimental and clinical cardiology.

[12]  A. Parkhomenko,et al.  Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. , 2012, International journal of cardiology.

[13]  G. Biondi-Zoccai,et al.  Milrinone and mortality in adult cardiac surgery: a meta-analysis. , 2012, Journal of cardiothoracic and vascular anesthesia.

[14]  Sean M. O'Brien,et al.  The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 1--coronary artery bypass grafting surgery. , 2009, The Annals of thoracic surgery.

[15]  T. Sarapohja,et al.  Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. , 2009, The Annals of thoracic surgery.

[16]  M. Singer,et al.  Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. , 2009, British journal of anaesthesia.

[17]  K. Murray,et al.  Milrinone Use Is Associated With Postoperative Atrial Fibrillation After Cardiac Surgery , 2008, Circulation.

[18]  B. Plaud,et al.  Perioperative Use of Dobutamine in Cardiac Surgery and Adverse Cardiac Outcome: Propensity-adjusted Analyses , 2008, Anesthesiology.

[19]  L. Tamer,et al.  Effects of levosimendan on myocardial ischaemia‐reperfusion injury , 2008, European journal of anaesthesiology.

[20]  D. Rubin.  Causal Inference Through Potential Outcomes and Principal Stratification: Application to Studies with “Censoring” Due to Death , 2006, math/0612783.

[21]  M. Oz,et al.  Coronary Artery Bypass Grafting in Patients With Low Ejection Fraction , 2005, Circulation.

[22]  E. Foster,et al.  Effects of Intravenous Levosimendan on Human Coronary Vasomotor Regulation, Left Ventricular Wall Stress, and Myocardial Oxygen Uptake , 2005, Circulation.

[23]  P. Pollesello,et al.  Effect of Levosimendan on Balance between ATP Production and Consumption in Isolated Perfused Guinea-Pig Heart before Ischemia or after Reperfusion , 2004, Journal of cardiovascular pharmacology.

[24]  P. Pollesello,et al.  Potassium-specific effects of levosimendan on heart mitochondria. , 2004, Biochemical pharmacology.

[25]  H. Oral,et al.  Changes in systemic sympathetic nervous system activity after mitral valve surgery and their relationship to changes in left ventricular size and systolic performance in patients with mitral regurgitation. , 2004, American heart journal.

[26]  P. Rosevear,et al.  Stereoselective binding of levosimendan to cardiac troponin C causes Ca2+-sensitization. , 2004, European journal of pharmacology.

[27]  H. Oral,et al.  Compared with control subjects, the systemic sympathetic nervous system is activated in patients with mitral regurgitation. , 2003, American heart journal.

[28]  G. Dorn.  Adrenergic pathways and left ventricular remodeling. , 2002, Journal of cardiac failure.

[29]  M. J. Smith,et al.  Relation of systemic sympathetic nervous system activation to echocardiographic left ventricular size and performance and its implications in patients with mitral regurgitation. , 2000, The American journal of cardiology.

[30]  H. Iida,et al.  Myocardial efficiency during levosimendan infusion in congestive heart failure , 2000, Clinical pharmacology and therapeutics.

[31]  D. Sawyer,et al.  Adrenergic regulation of myocardial apoptosis. , 2000, Cardiovascular research.

[32]  S G Thompson,et al.  Analysis and interpretation of cost data in randomised controlled trials: review of published studies , 1998, BMJ.

[33]  M. Nieminen,et al.  Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. , 1998, European heart journal.

[34]  P. Kaheinen,et al.  The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan. , 1997, Cardiovascular research.

[35]  J. Concato,et al.  A simulation study of the number of events per variable in logistic regression analysis. , 1996, Journal of clinical epidemiology.

[36]  C F Starmer,et al.  Clinical Judgment and Statistics: Lessons from a Simulated Randomized Trial in Coronary Artery Disease , 1980, Circulation.

[37]  B. Haldane.  THE ESTIMATION AND SIGNIFICANCE OF THE LOGARITHM OF A RATIO OF FREQUENCIES , 1956, Annals of human genetics.

[38]  Anthony O'Hagan,et al.  Assessing and comparing costs: how robust are the bootstrap and methods based on asymptotic normality? , 2003, Health economics.